We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow gained 0.66%, and the Nasdaq, a tech-heavy index, added 0.77%.
Coming into today, shares of the company had lost 18.21% in the past month. In that same time, the Medical sector lost 8.43%, while the S&P 500 lost 4.71%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$1.15, marking a 27.22% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $7.32 million, indicating a 741.03% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.85 per share and a revenue of $39.15 million, indicating changes of +25.04% and +1015.33%, respectively, from the former year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 1.51% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow gained 0.66%, and the Nasdaq, a tech-heavy index, added 0.77%.
Coming into today, shares of the company had lost 18.21% in the past month. In that same time, the Medical sector lost 8.43%, while the S&P 500 lost 4.71%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$1.15, marking a 27.22% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $7.32 million, indicating a 741.03% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.85 per share and a revenue of $39.15 million, indicating changes of +25.04% and +1015.33%, respectively, from the former year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 1.51% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.